Showing results (21-30 of 40) with videos related to

Sort By:
Pageof 4
Anticancer Research|May 30, 2008
Antitumoral and antiangiogenic efficacy of bisphosphonates in vitro and in a murine RENCA modelJens Soltau, Ute Zirrgiebel, Norbert Esser, et al.
Anticancer Research|July 28, 2004
Antiangiogenic potency of various chemotherapeutic drugs for metronomic chemotherapyJoachim Drevs, Julia Fakler, Silke Eisele, et al.
Graefe'S Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Fur Klinische Und Experimentelle Ophthalmologie|January 15, 2005
Intravitreal injection of specific receptor tyrosine kinase inhibitor PTK787/ZK222 584 improves ischemia-induced retinopathy in micePhilip Maier, Anke S Unsoeld, Bernd Junker, et al.
International Journal of Oncology|April 11, 2009
AMT: preclinical pharmacology studiesFaiz Niazi, Joachim Drevs, Klaus Diergarten, et al.
Oncology Reports|December 4, 2009
Anti-tumor effects of AMT in the renal cell carcinoma modelMarcello Caballero, Jürgen Scheele, Ute Zirrgiebel, et al.
Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism|December 25, 2002
Implications of vascular endothelial growth factor, sFlt-1, and sTie-2 in plasma, serum and cerebrospinal fluid during cerebral ischemia in manKai-Michael Scheufler, Joachim Drevs, Vera van Velthoven, et al.
Onkologie|December 8, 2007
Metronomic antiangiogenic therapy with capecitabine and celecoxib in advanced tumor patients--results of a phase II studySimone Steinbild, Jann Arends, Michael Medinger, et al.
Seminars in Oncology|June 13, 2003
Vascular endothelial growth factor receptor tyrosine kinase inhibitors: PTK787/ZK 222584Anne L Thomas, Bruno Morgan, Joachim Drevs, et al.
Pageof 4